深圳老年人流感与肺炎球菌双疫苗接种的成本效果分析
研究采用马尔可夫状态转移模型,比较深圳70-74岁人群接种流感与肺炎球菌双疫苗与不接种的成本效果,周期5年、周循环、社会视角、年贴现率5%。结果显示双疫苗接种可预防5042例流感感染、26例IPD、3例残疾和34例死亡,ICER为每获得1个QALY花费2699美元,具有成本效果。
要点
- 深圳70-74岁老年人接种流感与肺炎球菌双疫苗,5年内可预防5042例流感感染和34例死亡。
- 双疫苗接种相比不接种,ICER为每QALY 2699美元,低于2019年中国人均GDP(10289美元)的支付意愿阈值。
- 概率敏感性分析1000次模拟中,双疫苗接种在100%的重复中具有成本效果。
核心结论
- 深圳70-74岁老年人接种流感与肺炎球菌双疫苗是具成本效果的疾病预防策略。
研究设计与样本
- 采用周循环马尔可夫状态转移模型,比较深圳70-74岁人群接种流感与肺炎球菌双疫苗与不接种,时间跨度5年,模型允许流感活动季节性变化。
- 从社会视角计算增量成本效果比(ICER),成本与质量调整生命年(QALY)均按每年5%贴现,并进行单因素和概率敏感性分析(PSA)。
主要发现
- 基础案例分析中,双疫苗接种预防5042例流感感染、26例侵袭性肺炎球菌病(IPD)、3例残疾和34例死亡,人均成本7.1美元,净获得0.0026 QALYs。
- 以2019年中国人均GDP(10289美元)为支付意愿阈值,双疫苗接种的ICER为每QALY 2699美元,具有成本效果。
- 单因素敏感性分析显示ICER对流感发病率与流感疫苗效果的变化相对敏感。
- 基于1000次蒙特卡洛模拟的PSA结果,双疫苗接种在100%的重复中具有成本效果。
关键数值与推荐
- 双疫苗接种相比不接种的ICER为每QALY 2699美元。
- 支付意愿阈值采用2019年中国人均GDP 10289美元。
临床怎么用
- 可为深圳70-74岁老年人推荐流感与肺炎球菌双疫苗接种作为具成本效果的预防措施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost-effectiveness of dual influenza and pneumococcal vaccination for the elderly in Shenzhen, China. METHODS: A Markov state-transition model with a weekly cycle was developed to compare the outcomes of dual influenza and pneumococcal vaccination for the prevention of influenza and pneumococcal infections compared with no vaccination among 70-74 years old people in Shenzhen over 5 years. The model allowed seasonal variation of influenza activity. We calculated the incremental cost-effectiveness ratio (ICER) with costs and quality-adjusted life years (QALYs) discounted at 5% annually from the societal perspective. The impact of parameter uncertainty on the results was examined using one-way and probabilistic sensitivity analyses (PSA). RESULTS: In the base case, dual vaccination prevented 5042 influenza infections, 26 IPD cases, 3 disabilities, 34 deaths, and cost US$7.1 per person while resulting in a net gain of 0.0026 QALYs compared with no vaccination. Using once the Chinese gross domestic product per capita in 2019 (US$10,289) as the willingness-to-pay threshold, dual vaccination was cost-effective with an ICER of US$2699 per QALY gained. One-way sensitivity analyses showed that the ICER was relatively sensitive to changes in influenza attack rates and influenza vaccine effectiveness. Based on the results of PSA with 1000 Monte Carlo simulations, receiving both vaccines was cost-effective in 100% of the repetitions. CONCLUSION: The current study provides evidence that dual influenza and pneumococcal vaccination is a cost-effective disease prevention strategy for the elderly in Shenzhen, China.
引用
- Chen D, Ye Z, Pi Z, et al. Cost-effectiveness of dual influenza and pneumococcal vaccination among the elderly in Shenzhen, China. Vaccine. 2021. PMID: 33757667. doi:10.1016/j.vaccine.2021.03.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。